Procyrion has announced the closing of its series E round of funding. Photo via Getty Images

Houston-born and bred medical device company, Procyrion, has completed its series E with a raise of $57.7 million, including the conversion of $10 million of interim financing.

Procyrion is the company behind Aortix, a pump designed to be placed in the descending thoracic aorta of heart failure patients, which has been shown to improve cardiac performance in seriously ill subjects. The money raised will allow the company to proceed with a the DRAIN-HF Study, a pivotal trial that will be used for eventual FDA approval and commercialization.

The Aortix is the brainchild of Houston cardiologist Reynolds Delgado. According to Procyrion’s CSO, Jace Heuring, Delgado, gained some of his experience with devices for the heart working with legendary Texas Heart Institute surgeon O.H. “Bud” Frazier. He filed his first patents related to the Aortix in 2005.

Heuring says that the first prototypes were built in 2011, followed by the final design in 2018. CEO Eric Fain, a California-based MD and with more than 30 years in the medical device industry, joined the company in 2018 ahead of the final design, primed to bring Aortix to the public. He visits the company’s Houston headquarters, across the street from Central Market, on a regular basis.

The device’s pilot study of 18 patients was completed in 2022. Those encouraging results paved the way for the current study, which will include an enrollment of 134 patients. The randomized study will seek to treat patients with acute decompensated heart failure. Half will be treated with standard-of-care therapy, the other half will be catheterized with an Aortix pump. A separate arm of the study will seek to treat end-stage heart failure patients who would otherwise be deemed too sick for either a transplant or an LVAD permanent pump. Fort-five healthcare centers in the United States will participate, including Texas Heart Institute.

“One of the key characteristics is [the patients] are retaining a lot of fluid,” explains Heuring in a video interview. “And when I say a lot, I mean it could be 25 or 30 or 40 pounds of fluid or more. When we put our pump in, one of the main goals is to reduce that fluid load.”

On average, about 11 liters of fluid came off of each patient. Many of those end-stage patients had previously been considered for both a heart and kidney transplant, but after using the Aortix, their kidneys responded so well that they were able to get only the heart transplant.

“These patients really are in dire straits and come into the hospital and today the only proven therapy to help these patients is to administer high doses of intravenous diuretic and some other cardiac drugs and in about 25 percent of patients those therapies are ineffective,” says Fain.

If Aortix gains approval, these sickest of the sick, usually consigned to hospice care, will have hope.

Thanks to the Series E, led by Houston’s Fannin Partners, returning investors, including Bluebird Ventures, the Aortix is inching closer to commercialization. Besides funding the DRAIN-HR study, Procyrion will also use the funds for internal programs to improve product manufacturability. One more step towards meaning advanced heart failure may not always be a death sentence.

Last month, Atul Varadhachary, managing director of Fannin, joined the Houston Innovators Podcast and alluded to Procyrion's raise. The company was born out of Fannin and still resides in the same building as Fannin.

Aortix is a pump designed to be placed in the descending thoracic aorta of heart failure patients. Photo via Procyrion

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup acquired, plans to expand global medical device software solutions

exit this way

Houston-based Galen Data, a provider of cloud-based connectivity software for medical devices, has been acquired by health care-focused asset manager Lauxera Capital Partners. Financial terms weren’t disclosed.

Lauxera, based in France, says the Galen Data acquisition complements its 2022 purchase of Germany-based Matrix Requirements, a provider of software for medical device R&D and quality control teams.

“The Galen team has built an exceptional product providing medical device companies a cost-effective, compliant, and secure solution for medical device cloud connectivity,” Samuel Levy, founding partner of Lauxera, says in a news release.

Chris DuPont, co-founder and CEO of Galen Data, says the Lauxera deal “empowers us to take our business to the next level and better serve our clients while pushing forward the innovation that’s at the core of everything we do.”

Chris DuPont is the co-founder and CEO of Galen Data. Photo via LinkedIn

Galen Data had raised $7.21 million in venture capital since its founding in 2016, according to PitchBook. Investors included the Texas HALO Fund, the Houston Angel Network, Tamiami Angel Fund IV, and Zeeland Ventures. As of November 2023, Galen Data was valued at $18 million, according to Dealroom.co.

Customers of Galen Data include Austin-based Cardi/o, Houston-based Delphi Diagnostics, Houston-based Future Caridia, Austin-based Harmonic Bionics, Houston-based Tienovix, and Houston-based Zibrio.

4 fast-growing Houston tech companies secure spots on Deloitte list

big wins

Deloitte’s annual North America Technology Fast 500 list includes four Houston companies this year — all boasting of significant growth.

For Houston, Direct Digital Holdings, Inc. took the highest-ranking spot at No. 101 (up from 108 previous year) with 1,184 percent growth. NatGas Hub LLC (No. 286, 407 percent growth), Liongard (No. 437, 246 percent growth), and Stratus Medical LLC (No. 483, 212 percent growth) also made the list, which is an annual ranking of the fastest-growing North American companies in technology, energy tech sectors, telecommunications, life sciences, media, and fintech.

"Houston continues to demonstrate its prowess in fostering growth and technological advancement and I’m incredibly proud to see some of our local companies making significant strides and earning their well-deserved spots on the 2024 Deloitte Technology Fast 500 list,” Houston managing partner at Deloitte Melinda Yee says in a news release.

Award winners were selected based on fiscal year revenue growth from 2019 to 2022.

The companies achieved revenue growth ranging from 201 percent to 153,625 percent over the three-year time frame with an average growth rate of 1,981 percent and a median growth rate of 460 percent, according to a news release. Texas accounts for 6 percent of the winning companies with 73 percent of the companies from Texas are in the software sector.

“These companies exemplify the entrepreneurial spirit and innovative mindset that define Houston's dynamic business ecosystem,” Yee adds.

In 2023, the Houston representation looked similar. Direct Digital Holdings again topped the Houston rankings at No. 108, with Liongard, NatGasHub.com, and P97 Networks also showing substantial growth. As a state, Texas had 30 companies that made the list of the 541 ranked. In 2022, just one Houston company was recognized, as at No. 372 Onit reported revenue increase of 369 percent.

Biopharmaceutical company TG Therapeutics, Inc. was the No.1 spot in 2024 with a growth rate of 153,625 percent from 2020 to 2023. See the full list here.

Play it back: How this Houston innovator is championing women in health tech

HOUSTON INNOVATORS PODCAST EPISODE 264

With her long-standing career in health care, Ayse McCracken knows women are integral in leading health care. That's why she started Ignite Healthcare Network — to help find, support, and champion female health tech founders.

Originally founded in 2017 as a pitch competition, Ignite has evolved to become an active and integral program for female health tech entrepreneurs. Last month, the organization hosted its annual Fire Pitch Competition, and six finalists walked away with awards. At the event, the founders pitched their health tech solutions across lung health, renal therapy, breastfeeding tech, and more.

Last year, McCracken joined the Houston Innovators Podcast to share her story of starting Ignite and how its evolved since, accelerating around 100 female founders and advancing life-saving health care technology.

"Success to me isn't just getting people an early stage investment," she says on the show. "Success to me is getting companies that actually commercialize, get their products in the market, and that they are actually making an impact on health wellbeing, patients, and so forth."

"Having an impact in the health care industry and finding solutions is important to me," McCracken adds. "The second aspect of that is there are so many women in health care, and yet you don't see them in leadership roles."